This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
|Zacks Rank||Definition||Annualized Return|
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at email@example.com or call 800-767-3771 ext. 9339.
Intuitive Surgical (ISRG - Analyst Report) reported favorable fourth-quarter 2011 results. Earnings per share came in at $3.75, beating the Zacks Consensus Estimate of $3.34 and the year-ago earnings of $3.02. Net income climbed 24.8% year over year to $151.2 million.
Fourth Quarter Review
Revenues increased 28% year over year to $496.8 million, beating the Zacks Consensus Estimate of $483 million.
Instruments and accessories revenues were $196 million in the quarter, up 30% year over year. Worldwide procedures increased 27%. The company posted total systems revenue of $225 million in the quarter, up 27%. Services/Training revenues were $75 million in the quarter, up 24% year over year, primarily due to growth in the installed base of da Vinci Surgical systems.
We have discussed the quarterly results at length here: Intuitive Beats Squarely
Agreement – Estimate Revisions
Estimates for fiscal 2012 demonstrate an upward trend among the vast majority of analysts since the announcement of the fourth quarter results. Out of 14 analysts covering the stock, 11 have raised their estimates, for the current year, over the last 30 days with only 1 downward revision. There was no movement in either direction during the past week.
The movement of estimates, for 2013, was entirely weighted on the positive side with 7 upward revisions (out of 12 analysts) and no downward revision, over the past 30 days.
Magnitude – Consensus Estimate Trend
Positive revisions, coupled with sheer directional agreement, have led to an increase in annual forecasts for Intuitive Surgical. There has been an increase in estimates of 42 cents for 2012, and 89 cents for 2013, over the last 30 days. The current Zacks Consensus Estimate for fiscal 2012 is $14.49, reflecting an estimated 17.61% year-over-year increase.
Intuitive Remains “Neutral”
The company issued guidance for fiscal 2012, which was favorable. Total procedure count is forecast to increase between 24% and 26% for fiscal 2012. Revenues are expected to rise 17% to 19% for fiscal 2012. Operating income is projected in the range of 39% to 40% of revenues, which is in line with recent experience.
We expect a number of procedures that are currently completed either in an open surgical manner or with laparoscopy to be eventually replaced by da Vinci surgery, as robotic surgery becomes the standard of care in many instances. The company enjoys a virtual monopoly in robotic surgery with little competition.
Intuitive’s recurring revenue stream continues to grow and provides a shield against cyclicality of revenues, arising from the sale of discretionary capital equipment to hospitals. However, we believe that until the global economy recovers, the stock may come under pressure as investors ponder whether lingering macro economic uncertainty weakens hospitals’ commitment to buy high-cost robotic systems.
The pace of adoption of robotic surgery may therefore be lumpy and growth in usage requires acceptance from patients and training to medical practitioners. Intuitive competes with Accuray Incorporated (ARAY - Analyst Report) in certain niches.
We prefer to remain on the sidelines partly due to high valuation, which factors in the attractive growth prospects of the company, despite the da Vinci system’s leading status as an enabler of robotic minimally invasive surgery. We currently have a Neutral recommendation on Intuitive. The stock currently retains a Zacks #2 Rank, which translates into a short-term “Buy” recommendation.
About Earnings Estimate Scorecard
Len Zacks, PhD in mathematics from MIT, proved over 30 years ago that earnings estimate revisions are the most powerful force impacting stock prices. He turned this ground breaking discovery into two of the most celebrating stock rating systems in use today. The Zacks Rank for stock trading in a 1 to 3 month time horizon and the Zacks Recommendation for long-term investing (6+ months). These “Earnings Estimate Scorecard” articles help analyze the important aspects of estimate revisions for each stock after their quarterly earnings announcements. Learn more about earnings estimates and our proven stock ratings at http://www.zacks.com/education/.
Please login to Zacks.com or register to post a comment.